This webinar provides insight into proper evaluation of compound-induced hypercoagulability and platelet interference, and you will learn how accounting for this potential complication in the safety phase of your program can help you to avoid/reduce the potential for thrombosis in the clinic.

We’ll cover:

  • Biomarkers to properly evaluate hypercoagulability
  • Use of flow cytometry and aggregometry for in vivo and ex vivo evaluations of platelet activation and aggregation
  • Assessments for combined compound effects on platelet aggregation


  • Florence Poitout, DAVCP, DECVCP, Senior Director, Clinical Pathology, Charles River
  • Paolo Campoli, MSc, Research Scientist, Immunology, Charles River